It should be excluded before the beginning of therapy that the patient is likely to have malignant tumors in the duodenum, esophagus or stomach, due to the ability of the drug "Famotidine" to hide symptoms.
Kufanele babe yingxenye ngaphambi kokuqala imishanguzo, ematfuba kokuba isiguli izimila ebulalayo kule duodenum, emphinjeni noma esiswini, ngenxa ikhono zomuthi "famotidine" ukufihla izimpawu.